SION
NASDAQSionna Therapeutics Inc.
News25/Ratings12
News · 26 weeks55+300%
2026-03-012026-08-23
Mix3290d
- Insider16(50%)
- Analyst7(22%)
- SEC Filings6(19%)
- Other2(6%)
- Earnings1(3%)
Latest news
25 items- ANALYSTSionna Therapeutics downgraded by BTIG ResearchBTIG Research downgraded Sionna Therapeutics from Buy to Neutral
- ANALYSTSionna Therapeutics downgraded by GuggenheimGuggenheim downgraded Sionna Therapeutics from Buy to Neutral
- ANALYSTSionna Therapeutics downgraded by CitizensCitizens downgraded Sionna Therapeutics from Mkt Outperform to Mkt Perform
- ANALYSTSionna Therapeutics upgraded by RBC Capital Mkts with a new price targetRBC Capital Mkts upgraded Sionna Therapeutics from Underperform to Sector Perform and set a new price target of $5.00
- ANALYSTSionna Therapeutics downgraded by Raymond JamesRaymond James downgraded Sionna Therapeutics from Strong Buy to Mkt Perform
- ANALYSTSionna Therapeutics downgraded by Wedbush with a new price targetWedbush downgraded Sionna Therapeutics from Outperform to Neutral and set a new price target of $5.00
- ANALYSTSionna Therapeutics downgraded by Stifel with a new price targetStifel downgraded Sionna Therapeutics from Buy to Hold and set a new price target of $7.00
- SECSEC Form 8-K filed by Sionna Therapeutics Inc.8-K - Sionna Therapeutics, Inc. (0002036042) (Filer)
- PRSionna Therapeutics Reports Topline Data from Two Development Programs in Cystic Fibrosis and Provides Corporate UpdateSION-719 Phase 2a proof-of-concept trial did not achieve key activity endpoint of sweat chloride reduction when added to standard of care; Company is not advancing SION-719 as an add-on to standard of care Potential confounders in SION-719 Phase 2a trial are being evaluated to inform next steps for the SION-451 dual combination clinical program Ended Q2 with approximately $268.3 million in cash and plans to take actions to preserve capital while evaluating next steps Sionna to host conference call today at 8:00 a.m. ET WALTHAM, Mass., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (NASDAQ:SION), a clinical-stage biopharmaceutical company on a mission to develop novel medic
- SECSEC Form 10-Q filed by Sionna Therapeutics Inc.10-Q - Sionna Therapeutics, Inc. (0002036042) (Filer)
- SECSionna Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - Sionna Therapeutics, Inc. (0002036042) (Filer)
- PRSionna Therapeutics Reports Second Quarter 2026 Financial ResultsPreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care is on track for topline data summer of 2026 Phase 1 trial evaluating NBD1 stabilizer SION-451 in proprietary dual combinations with SION-2222 and with SION-109 also is on track for topline data summer of 2026 Maintained strong cash position with $268.3 million in cash and cash equivalents, expected to fund operations into 2028 WALTHAM, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (NASDAQ:SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) today reported financial results
- INSIDERDirector Thompson Peter A. sold $3,854,281 worth of shares (85,918 units at $44.86) as part of a pre-agreed trading plan (SEC Form 4)4 - Sionna Therapeutics, Inc. (0002036042) (Issuer)
- INSIDERDirector Orbimed Advisors Llc sold $3,854,281 worth of shares (85,918 units at $44.86) as part of a pre-agreed trading plan (SEC Form 4)4 - Sionna Therapeutics, Inc. (0002036042) (Issuer)
- INSIDERChief Legal Officer Fitzpatrick Jennifer exercised 10,250 shares at a strike of $6.11 and sold $446,862 worth of shares (10,250 units at $43.60) as part of a pre-agreed trading plan (SEC Form 4)4 - Sionna Therapeutics, Inc. (0002036042) (Issuer)
- INSIDERDirector Thompson Peter A. sold $5,270,902 worth of shares (115,844 units at $45.50) as part of a pre-agreed trading plan (SEC Form 4)4 - Sionna Therapeutics, Inc. (0002036042) (Issuer)
- INSIDERDirector Orbimed Advisors Llc sold $5,270,902 worth of shares (115,844 units at $45.50) as part of a pre-agreed trading plan (SEC Form 4)4 - Sionna Therapeutics, Inc. (0002036042) (Issuer)
- INSIDERSEC Form 4 filed by Director Stelzer Laurie4 - Sionna Therapeutics, Inc. (0002036042) (Issuer)
- INSIDERSEC Form 4 filed by Director Viney Joanne L.4 - Sionna Therapeutics, Inc. (0002036042) (Issuer)
- INSIDERSEC Form 4 filed by Director Thompson Peter A.4 - Sionna Therapeutics, Inc. (0002036042) (Issuer)
- INSIDERSEC Form 4 filed by Director Ra Capital Management, L.P.4 - Sionna Therapeutics, Inc. (0002036042) (Issuer)
- INSIDERSEC Form 4 filed by Director Ruddy Marcella K.4 - Sionna Therapeutics, Inc. (0002036042) (Issuer)
- INSIDERSEC Form 4 filed by Director Resnick Joshua4 - Sionna Therapeutics, Inc. (0002036042) (Issuer)
- INSIDERSEC Form 4 filed by Director Fleming Harold Edward4 - Sionna Therapeutics, Inc. (0002036042) (Issuer)
- INSIDERSEC Form 4 filed by Director Clancy Paul J4 - Sionna Therapeutics, Inc. (0002036042) (Issuer)
SION FAQ
6 questionsWhere does SION stock trade?
Sionna Therapeutics Inc. (SION) is listed on NASDAQ.What sector and industry is SION in?
Sionna Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Sionna Therapeutics Inc. go public?
Sionna Therapeutics Inc. (SION) completed its IPO in 2025.What are analysts saying about SION?
Sionna Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from BTIG Research: Neutral on 2026-08-10. Recent price targets range from $500.00 to $700.00.What companies are similar to SION?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare SION side-by-side with any of them on Quantisnow.How can I track SION on Quantisnow?
Quantisnow aggregates Sionna Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SION to receive live email and push alerts on every new disclosure.